Product Overview

Duphaston 10 mg is a prescription tablet that contains the synthetic progestogen dydrogesterone as the active pharmaceutical ingredient. Produced by Abbott India Pvt. Ltd., each strip comprises ten tablets of 10 mg strength, and the product is marketed in pack sizes of 30, 60, and 90 tablets to accommodate varying treatment durations. Clinically, Duphaston is indicated for three principal gynecological conditions: endometriosis, support of female infertility associated with luteal phase deficiency, and the mitigation of pain linked to menstrual cycles (dysmenorrhea). The medication is formulated for oral administration and is distributed after a typical order‑to‑delivery window of six to fifteen days, depending on the logistics provider.

What is Duphaston?

Duphaston belongs to the class of progestational agents that exert their biological activity by binding selectively to the intracellular progesterone receptor. Chemically, dydrogesterone is described as 6‑deoxy‑6‑α‑methyl‑17‑α‑hydroxy‑progesterone acetate, a structural analog of natural progesterone that retains the ability to modulate endometrial gene expression while displaying minimal androgenic, anti‑androgenic, or mineralocorticoid activity. This selectivity confers a favorable tolerability profile, making the drug suitable for long‑term use in women of reproductive age who require hormonal support without the typical side‑effects associated with more potent progestins such as norethisterone or medroxyprogesterone acetate. The drug undergoes hepatic metabolism to inactive metabolites that are eliminated primarily via the renal route, and its pharmacokinetic parameters are characterized by a relatively short half‑life, which supports steady‑state achievement with multiple daily dosing.

Uses and Benefits

The therapeutic repertoire of Duphaston spans several evidence‑based applications. In endometriosis, continuous administration of 10 mg twice daily has been shown in randomized controlled trials to reduce lesion size, decrease inflammatory cytokines, and alleviate chronic pelvic pain, thereby improving quality of life scores. For infertility linked to luteal phase deficiency, the addition of Duphaston during assisted reproductive technologies (ART) can enhance endometrial receptivity by stabilizing the secretory phase, a factor that is critical for embryo implantation. Moreover, the medication provides symptomatic relief in dysmenorrhea by attenuating uterine contractility and reducing prostaglandin synthesis, which together diminish the intensity and duration of menstrual cramps. The oral route of delivery simplifies patient adherence compared with injectable or transdermal progestins, and the availability of multiple pack sizes enables clinicians to tailor the treatment course to individual patient needs.

How It Works

At the molecular level, dydrogesterone functions as a full agonist at the progesterone receptor, triggering transcription of genes that promote secretory transformation of the endometrium and inhibit proliferative signaling pathways. Because the compound is metabolized to inactive 6‑hydroxy‑dydrogesterone and its conjugates, it avoids accumulation and minimizes off‑target interactions. This mechanistic profile underlies its efficacy in suppressing ectopic endometrial activity in endometriosis, as well as its role in creating a hormonally supportive environment for early pregnancy maintenance. The drug’s low affinity for mineralocorticoid and androgen receptors reduces the likelihood of fluid retention, hypertension, or virilizing effects, which are commonly observed with higher‑potency progestins.

Dosage Guidelines

Recommended dosing regimens are condition‑specific and should always be individualized by a qualified healthcare professional. For endometriosis, the standard protocol involves 10 mg administered twice daily for a minimum of twelve weeks; extension beyond this period is determined by clinical response and tolerability. In the context of IVF‑embryo transfer, a common adjunctive regimen consists of 10 mg taken three times per day beginning on the day of transfer and continuing for approximately fourteen days to support luteal phase function. For dysmenorrhea, a short‑term course of 10 mg twice daily during the symptomatic phase of menstruation is often sufficient to achieve pain relief. Tablets should be swallowed whole with a full glass of water, and they may be taken with or without food. Patients are advised not to alter the prescribed dose without medical consultation, and missed doses should be taken as soon as remembered unless it is near the time of the next scheduled dose, in which case the missed dose should be skipped.

Side Effects

Adverse reactions to Duphaston are generally mild and transient, reflecting its selective receptor profile. The most frequently reported events include abdominal discomfort, nausea, mild headache, breast tenderness, and occasional fatigue. Less common occurrences comprise dizziness, peripheral edema, and skin manifestations such as pruritus or maculopapular rash. Rare but clinically significant complications can involve elevations in hepatic transaminases, cholestasis, or thromboembolic phenomena, particularly in patients with pre‑existing risk factors such as smoking, obesity, or a personal history of venous thromboembolism. Any persistent gastrointestinal disturbances, unexplained weight gain, or signs of allergic reaction warrant immediate medical evaluation. It is essential for patients to report all new or worsening symptoms to their prescribing clinician promptly.

Warnings and Precautions

Duphaston is contraindicated in individuals with a known hypersensitivity to dydrogesterone or any of the excipients present in the formulation. Caution is advised in patients with severe hepatic impairment, as dose modification may be necessary to prevent accumulation of metabolites. The medication should be used during pregnancy only when the anticipated benefit justifies the potential risk, and only under the direct supervision of a qualified obstetrician. Breast‑feeding mothers should discuss the risks and benefits with their physician, as only limited data are available regarding the excretion of dydrogesterone into human milk. Concomitant administration of strong cytochrome P450 enzyme inducers (e.g., rifampicin, carbamazepine) may reduce systemic exposure, whereas inhibitors (e.g., ketoconazole) could increase levels; therefore, a comprehensive medication review is recommended prior to initiation. Patients with a history of thromboembolic disease, or those possessing multiple risk factors such as advanced age, smoking, or hypercoagulable states, should be monitored closely with periodic laboratory assessments.

Frequently Asked Questions

Q1: What is the primary therapeutic use of Duphaston 10 mg?
A: Duphaston is prescribed primarily for the management of endometriosis, the treatment of female infertility related to luteal phase deficiency, and the alleviation of painful menstruation (dysmenorrhea).

Q2: How should Duphaston be stored?
A: Store the tablets at room temperature, away from moisture, heat, and direct sunlight. Keep the strip sealed until ready for use, and ensure it is inaccessible to children.

Q3: Can Duphaston be taken together with other hormonal medications?
A: Concomitant use with other progestins, estrogen‑containing products, or hormonal contraceptives should be avoided unless explicitly directed by a physician, as it may increase the risk of hormonal imbalance or adverse effects.

Q4: Is long‑term use of Duphaston considered safe?
A: Clinical studies have demonstrated that Duphaston is well tolerated during treatment courses extending up to six months, provided that patients are monitored regularly for side effects and laboratory parameters. Longer durations require individualized risk‑benefit assessment by a healthcare professional.

Q5: Where can I find authoritative information on dydrogesterone regulatory status?
A: Detailed prescribing information and regulatory approvals are published on the U.S. Food and Drug Administration (FDA) website (https://www.fda.gov/drugs) and the National Institutes of Health’s PubMed database (https://www.ncbi.nlm.nih.gov/pubmed). Additional consumer‑focused guidance is available from the NIH Office of Dietary Supplements and MedlinePlus.

Related Products

• Faceclin Gel (Clindamycin/Nicotinamide)
• Resteclin 500 mg (Tetracycline)
• Erythrocin 250 mg (Erythromycin)
• Flagyl 200mg (Metronidazole)
• Flagyl 400mg (Metronidazole)
• Flagyl (Metronidazole)
• Tetracycline 500 mg (Generic)
• Tetracycline 250 mg (Generic)
• Resteclin (Tetracycline)
• Resteclin 250 mg (Tetracycline)
• Erythrocin (Erythromycin)
• Bactrim DS (Sulfamethoxazole/Trimethoprim)